Fluorofenidone protects against acute liver failure in mice by regulating MKK4/JNK pathway
Lei Gu,Xin He,Yanqiu Zhang,Shenglan Li,Jie Tang,Ruixue Ma,Xinyi Yang,Hao Huang,Yu Peng,Yanyun Xie,Zhangzhe Peng,Jie Meng,Gaoyun Hu,Lijian Tao,Xiaowei Liu,Huixiang Yang
DOI: https://doi.org/10.1016/j.biopha.2023.114844
2023-05-24
Abstract:Aims Acute liver failure (ALF) is a life-threatening disease characterized by abrupt and extensive hepatic necrosis and apoptosis, resulting in high mortality. The approved drug, N-acetylcysteine (NAC), is only effective for acetaminophen (APAP)-associated ALF at the early stage. Thus, we investigate whether fluorofenidone (AKF-PD), a novel antifibrosis pyridone agent, protects against ALF in mice and explore its underlying mechanisms. Methods ALF mouse models were established using APAP or lipopolysaccharide/ D -galactosamine (LPS/ D -Gal). Anisomycin and SP600125 were used as JNK activator and inhibitor, respectively, and NAC served as a positive control. Mouse hepatic cell line AML12 and primary mouse hepatocytes were used for in vitro studies. Results AKF-PD pretreatment alleviated APAP-induced ALF with decreased necrosis, apoptosis, reactive oxygen species (ROS) markers, and mitochondrial permeability transition in liver. Additionally, AKF-PD alleviated mitochondrial ROS stimulated by APAP in AML12 cells. RNA-sequencing in the liver and subsequent gene set enrichment analysis showed that AKF-PD significantly impacted MAPK and IL-17 pathway. In vitro and in vivo studies demonstrated that AKF-PD inhibited APAP-induced phosphorylation of MKK4/JNK, while SP600125 only inhibited JNK phosphorylation. The protective effect of AKF-PD was abolished by anisomycin. Similarly, AKF-PD pretreatment abolished hepatotoxicity caused by LPS/ D -Gal, decreased ROS levels, and diminished inflammation. Furthermore, unlike NAC, AKF-PD, inhibited the phosphorylation of MKK4 and JNK upon pretreatment, and improved survival in cases of LPS/ D -Gal-induced mortality with delayed dosing. Conclusions In summary, AKF-PD can protect against ALF caused by APAP or LPS/ D -Gal, in part, via regulating MKK4/JNK pathway. AKF-PD might be a novel candidate drug for ALF.
pharmacology & pharmacy,medicine, research & experimental